A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

NCT07597018 · Not yet recruiting

Last updated 2026-05-28

This study compares how different versions of the drug cagrilintide are absorbed into the bloodstream over time in adults who are overweight or have obesity.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 234 people Planned (estimated).

Who can join Ages 18–64 · all sexes

Timeline Started 2026-05 · est. completion 2027-05

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT07597018 ↗

Description as written by the study sponsor.

This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide version D or cagrilintide version B, and which treatment participants receive is decided by chance. Participants will be in this clinical study for about 6 months.

Treatments tested

Cagrilintide D Drug

Cagrilintide D will be administered subcutaneously.
Cagrilintide B and placebo semaglutide I Drug

Cagrilintide B and placebo semaglutide I will be administered subcutaneously

Main thing measured	AUC,ss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide s.c.
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity, Overweight
GLP-1 drugs	cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07597018 ↗